(2)a description of the organisational structure of the marketing authorisation holder, including the list of the site(s) where the following pharmacovigilance activities are undertaken: individual case safety report collection, evaluation, safety database case entry, periodic safety update report production, signal detection and analysis, preparation, implementation and maintenance of a risk management plan, pre- and post-authorisation study management, and management of safety variations of the terms of a marketing authorisation.’;